Neuroprotection Research Market

NA-Selank Amidate

An N-acetylated, amidated form of Selank designed for enhanced stability and nasal bioavailability, studied for anxiolytic and nootropic effects via tuftsin-related immune modulation.

AnxietyNootropicImmuneSelank

Also referenced as: N-Acetyl Selank Amidate, NASA

Also appears in: Immune

Vial price compare
24 tracked offers across 24 vendors · 12 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $0.96/mg
From
$0.96/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-14.0% vs. Sep 7
Current low$0.96/mg
Market median$3.33/mg
Current coverage9 vendors
Observed window90 daily points
Lowest effective price Market median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when N-Acetyl Selank Amidate crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence 17 certificate records for NA-Selank Amidate products, from 6 vendors 12 reference a report on the testing laboratory's own system · 3 have a laboratory lookup that answered when last checked · 14 match a vendor product page at the same address
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Neuroprotection

Primary research area: Neuroprotection. Also surfaces under Immune for browsing and discovery.

Aliases
2

N-Acetyl Selank Amidate, NASA

Signal depth
Medium

No FDA label signal · 468 trials · 16009 PubMed results

Preclinical
Research evidence

Current evidence for NA-Selank Amidate is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

NA-Selank Amidate has 1 name-matched clinical trial (highest phase: no phased trial) and 16009 PubMed-indexed publications and is not FDA-approved.

Human data
Human (non-phased)
Trial quality
Observational
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
Trial Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA) Advances in psychology · 14,931 citations Development of NASA-TLX (Task Load Index): Results of Empirical and Theoretical Research Proceedings of the Human Factors and Ergonomics Society Annual Meeting · 4,307 citations Nasa-Task Load Index (NASA-TLX); 20 Years Later Atmospheric chemistry and physics · 2,179 citations Asian emissions in 2006 for the NASA INTEX-B mission Journal Article The learning curve associated with robotic-assisted shoulder arthroplasty: A feasibility study. Journal Article Preliminary usability evaluation of a teleoperated humanoid robot for pediatric waiting-room observation: clinical and technical professionals' perspectives.
Evidence history
  1. 2026-10-03 Promising → Preclinical Band Promising → Preclinical; -14 trials; +2 PubMed
  2. 2026-10-01 Preclinical → Promising Band Preclinical → Promising; +19 trials; +1 PubMed
  3. 2026-09-30 Promising → Preclinical Band Promising → Preclinical; -19 trials; +1 PubMed
  4. 2026-09-29 Preclinical → Promising Band Preclinical → Promising; +1 PubMed
  5. 2026-09-26 Early → Preclinical Band Early → Preclinical; +1 PubMed
  6. 2026-09-25 Preclinical → Early Band Preclinical → Early; +19 trials; +5 PubMed
  7. 2026-09-24 Early → Preclinical Band Early → Preclinical; -14 trials; +3 PubMed
  8. 2026-09-23 Preclinical → Early Band Preclinical → Early; +14 trials; +4 PubMed
  9. 2026-09-11 Promising → Preclinical Band Promising → Preclinical; -4 trials; +1 PubMed
  10. 2026-09-10 Preclinical → Promising Band Preclinical → Promising; +9 trials; +4 PubMed
  11. 2026-09-09 Promising → Preclinical Band Promising → Preclinical; -9 trials
  12. 2026-09-04 Preclinical → Promising Band Preclinical → Promising; +9 trials; +4 PubMed
  13. 2026-09-03 Promising → Preclinical Band Promising → Preclinical; -4 trials; +13 PubMed
  14. 2026-09-01 Preclinical → Promising Band Preclinical → Promising; +4 trials
  15. 2026-08-28 Promising → Preclinical Band Promising → Preclinical; -13 trials; +7 PubMed
  16. 2026-08-22 Preclinical → Promising Band Preclinical → Promising; +9 trials; +2 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-05 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is NA-Selank Amidate?

NA-Selank Amidate is a modified version of Selank, a synthetic heptapeptide analog of tuftsin (the naturally occurring immunomodulatory peptide fragment of IgG). The modifications — N-acetylation at the N-terminus and amidation at the C-terminus — are designed to improve resistance to enzymatic degradation and extend the peptide’s biological half-life compared to unmodified Selank.

How it works

The core mechanism is shared with Selank:

  • Tuftsin pathway — Selank is a synthetic extension of tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide released from the Fc domain of IgG during phagocytosis. Tuftsin stimulates phagocytic activity of monocytes and neutrophils (Nishioka, Molecular and Cellular Biochemistry, 1979)
  • GABA modulation — Selank has been shown to modulate GABA-A receptor sensitivity and influence BDNF expression in the hippocampus (Semenova et al., Doklady Biological Sciences, 2010)
  • Anxiolytic effects — In preclinical models, Selank showed anxiolytic activity comparable to benzodiazepines without sedation or dependence (Seredenin et al., Bulletin of Experimental Biology and Medicine, 1998)
  • Enhanced stability — the N-acetyl and amide modifications reduce aminopeptidase and carboxypeptidase degradation, extending the effective duration per administration

Research status

Selank (the parent peptide) has more clinical data than most research peptides, though primarily in Russian literature:

  • Zozulya et al. (2008) reviewed the anxiolytic and nootropic properties of Selank in clinical and preclinical settings (Zhurnal Nevrologii i Psikhiatrii, 108(4):50–57)
  • Seredenin et al. (1998) demonstrated anxiolytic effects of Selank in elevated plus-maze and conflict tests (Bulletin of Experimental Biology and Medicine, 126(4):1079–1082)
  • Selank is approved in Russia as an intranasal anxiolytic (registration: PN002160)

The specific NA-Amidate modification has not been studied in published clinical trials — it is a vendor-driven formulation designed for improved stability.

Key considerations

  • Selank (the parent compound) has Russian regulatory approval, which is unusual for research peptides
  • The NA-Amidate form is not the version studied in clinical trials — it is a stability modification for the research market
  • Typically administered intranasally from research vendors (spray formulations)
  • Often stacked with NA-Semax Amidate, the analogous modified form of the nootropic peptide Semax